FBIO (Fortress Biotech) GF Score : 63/100 (As of Mar. 26, 2025)

View and export this data going back to 2011. Start your Free Trial

What is Fortress Biotech GF Score?

Fortress Biotech has the GF Score of 63, which implies that the company might have Poor future performance potential.

The GF Score is a stock performance ranking system developed by GuruFocus using five aspects of valuation, which has been found to be closely correlated to the long-term performances of stocks by backtesting from 2006 to 2021. The stocks with a higher GF Score generally generate higher returns than those with lower GF Scores. Therefore, when picking stocks, investors should invest in companies with high GF Scores. The GF Score ranges from 0 to 100, with 100 as the highest rank.

GF Score takes following five key aspects into consideration:

1. Financial Strength : 3/10
2. Profitability Rank : 1/10
3. Growth Rank : 8/10
4. GF Value Rank : 2/10
5. Momentum Rank : 7/10

Each one of these components is ranked and the ranks also have positive correlation with the long term performances of stocks. The GF score is calculated using the five key aspects of analysis. Through backtesting, we know that each of these key aspects has a different impact on the stock price performance. Thus, they are weighted differently when calculating the total score. The Profitability Rank and the Growth Rank are weighted fully, while other parameters have less weight.

Based on research and backtesting result, GuruFocus believes Fortress Biotech might have Poor future performance potential.

Please click GF Score to see more details on the GF Score's 5 Key Aspects of Analysis.

Competitive Comparison of Fortress Biotech's GF Score

For the Biotechnology subindustry, Fortress Biotech's GF Score, along with its competitors' market caps and GF Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Fortress Biotech's GF Score Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Fortress Biotech's GF Score distribution charts can be found below:

* The bar in red indicates where Fortress Biotech's GF Score falls into.

Fortress Biotech (NAS:FBIO) GF Score Explanation

Based on the historical long-term performances among five valuation aspects, the GF Score is found to be closely correlated to the long-term performances of stocks. It ranges from 0 to 100, with 100 as the highest. GuruFocus divided GF Score into following 5 categories:

GF Score	Performance Potential and All-in-One Screener Examples ⁽¹⁾
91 - 100	Highest outperformance potential
81 - 90	Good outperformance potential
71 - 80	Likely to have average performance
51 - 70	Poor future performance potential
0 - 50	Worst future performance potential, or not enough data

(1) These are some simple examples. You can access our GF Score filter under All-in-One Screener’s Fundamental tab.

Fortress Biotech GF Score Related Terms

Thank you for viewing the detailed overview of Fortress Biotech's GF Score provided by GuruFocus.com. Please click on the following links to see related term pages.

Fortress Biotech Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Fortress Biotech Inc (NAS:FBIO) » Definitions » GF Score

Comparable Companies

Traded in Other Exchanges

FBIOP.PFD:USA CNB0.PFD:Germany

Address

1111 Kane Concourse, Suite 301, Bay Harbor Island, FL, USA, 33154

Website

https://www.fortressbiotech.com

Fortress Biotech Inc is a biopharmaceutical company. The firm is involved in the business of acquiring, developing, and commercializing pharmaceutical and biotechnology products. Its product portfolio encompasses Qbrexza, Accutane, Amzeeq, Zilxi, Targadox, Ximino, and Exelderm. The business activities of the group are functioned through Dermatology Product Sales, and Pharmaceutical and Biotechnology Product Development. It derives the majority of its revenues from Dermatology segment. Its subsidiaries also operate in biotechnology, pharmaceutical, oncology, therapeutics sectors.

Executives

Rosenwald Lindsay A Md	director, 10 percent owner, officer: PRESIDENT, CEO & CHAIRMAN	375 PARK AVE, NEW YORK NY 10152
Dov Klein	director	C/O FORTRESS BIOTECH, INC., 3 COLUMBUS CIRCLE, 15TH FLOOR, NEW YORK NY 10019
Lucy Lu	director	THE FEMALE HEALTH COMPANY, 4400 BISCAYNE BOULEVARD, SUITE 888, MIAMI FL 33137
David Jin	officer: Chief Financial Officer	C/O AVENUE THERAPEUTICS, INC., 1140 AVENUE OF THE AMERICAS, FLOOR 9, NEW YORK NY 10036
Robyn Hunter	officer: Chief Financial Officer	95 SAWYER ROAD, SUITE 110, WALTHAM MA 02453
Eric K Rowinsky	director	IMCLONE SYSTEMS INCORPORATED, 180 VARICK STREET, 6TH FLOOR, NEW YORK NY 10014
Malcolm Hoenlein	director	750 LEXINGTON AVENUE, NEW YORK NY 10022
Jimmie Harvey	director	3741 EAST FAIRWAY DRIVE, BIRMINGHAM AL 35213
J Jay Lobell	director	365 W END AVE, APARTMENT 10A, NEW YORK NY 10024
Michael S Weiss	director, 10 percent owner, officer: EXECUTIVE VICE CHAIRMAN	750 LEXINGTON AVE, NEW YORK NY 10022
Kevin Lorenz	director	C/O NUVEEN, 333 W. WACKER DR., CHICAGO IL 60606
George Avgerinos	officer: SVP, Biologics Operations	C/O CORONADO BIOSCIENCES, INC., 24 NEW ENGLAND EXECUTIVE PARK, BURLINGTON MA 01803
Kevin Horgan	other: Former Chief Medical Officer	C/O SOLIGENIX, INC., 29 EMMONS DRIVE, STE. C-10, PRINCETON NJ 08540
David Jonathan Barrett	director	ONE PENN PLAZA, SUITE 2514, NEW YORK NY 10119
Harlan F Weisman	director	C/O CORONADO BIOSCIENCES, INC., 15 NEW ENGLAND EXECUTIVE PARK, BURLINGTON MA 01803